



eCQMs 101

Getting Started with Electronic Clinical Quality Measures



Today's presenter

Kristen Beatson

Director, Electronic Measures

kbeatson@medisolv.com

Agenda:

- Understanding eCQMs
- Implementing eCQMs
- Analysis & Monitoring of eCQMs
- CMS IQR Program
- TJC ORYX Program
- Q&A

CMS Statement

“After holding eCQM reporting and submission policies constant for a number of years in order to give hospitals and their vendors additional time to improve eCQM reporting capabilities, and stating our intention to transition to more robust reporting, we believe that it is time to increase the level of reporting...”

TJC Statement

“The eCQMs used by The Joint Commission are updated on an annual basis to account for changes in clinical evidence, measure logic, and coding updates. *The Joint Commission maintains close alignment with CMS measures where possible and continues to advance eCQM development to drive quality improvement...*”



Year 1: Building the Foundation



Identify Team & Resources



Review Regulatory Requirements



Organize, Review & Educate: Measures, specifications...



Gap Analysis and Roadblocks



Implementation: Plan, Build, Map, Educate



Validate



Monitor & Improve



Gaps and Roadblocks




Submit



Return to Start

Identify Team & Resources

(and make sure everyone understands)



Understanding eCQMs

Clinical Quality Measures:

“Tools that help measure and track the quality of health care services provided by eligible professionals, eligible hospitals and critical access hospitals (CAHs) within our health care system” - CMS.gov


- Clinical Processes
- Patient Safety
- Treatments
- Outcomes

Electronic Clinical Quality Measures:

“eCQMs use data from electronic health records (EHR) and/or health Information technology systems to measure health care quality”
- eCQI Resource Center


Understanding eCQMs

Manual Abstraction Process



Understanding eCQMs

eCQM Process



Resources



Specifications



Data Elements



Value Sets



Best Practices



Internal Support



External Support



Technical

- eCQI Resource Center
- Quality Net
- CMS
- TJC
- JIRA
- VSAC
- Vendors

Review Regulatory Requirements

IQR: 2021 eCQMs



REQUIREMENT:

Hospitals must submit 2 Quarters and at least 4 of the available 9 eCQMs



SUBMISSION METHOD:

QualityNet Secure Portal



DEADLINE:

Annual Submission Deadline of February 2022

IQR: 2021 eCQMs

2021:

- 2 self-selected quarters
- Minimum of 4 self-selected eCQMs
- Addition of CMS 506: Safe Use of Opioids – Concurrent Prescribing
- Publicly reported on Hospital Compare

| | | |
|-------|-------|-------|
| VTE-1 | VTE-2 | STK-6 |
| STK-5 | PC-05 | STK-3 |
| ED-2 | STK-2 | OPI-1 |

IQR: 2022 eCQMs

2022:

- 3 self-selected quarters
- Minimum of 4 eCQMs
 - ✓ 3 self-selected eCQMs
 - ✓ 1 required: Safe Use of Opioids – Concurrent Prescribing
- Publicly reported on Hospital Compare

| | | |
|-------|-------|-------|
| VTE-1 | VTE-2 | STK-6 |
| STK-5 | PC-05 | STK-3 |
| ED-2 | STK-2 | OPI-1 |

Hybrid Hospital-Wide Readmission Measure

- Claims and Electronic Health Record Data
- 2 years of **voluntary** reporting:
July 1, 2021-June 30, 2022; July 1, 2022 -June 30, 2023
- Electronic specifications available Spring 2020
- Confidential hospital-specific feedback reports
- Voluntary submissions will not be publicly reported and will not impact payment determination

Beginning with the FY 2026 payment determination

- Remove Claims-Based Hospital-Wide All-Cause Readmission measure
- Replace with **required** Hybrid HWR Reporting for the Period:
July 1, 2023-June 30, 2024
- Publicly reported on Hospital Compare

ORYX: 2021 eCQMs




REQUIREMENT:

Hospitals must submit 2 Quarters and at least 4 of the available **12** eCQMs



SUBMISSION METHOD:

Direct Data Submission Platform (DDSP)



DEADLINE:

Annual Submission Deadline of March 15, 2022

ORYX: 2021 eCQMs

2021:

- 2 self-selected quarters (do not need to be consecutive)
- Minimum 4 self-selected eCQMs (submit the same measures for both quarters)
- Addition of CMS 506: Safe Use of Opioids Concurrent Prescribing & ePC-06: Unexpected Complications in Term Newborns

| | | | |
|--------------|-----------------------------|-----------------------------|-----------------------------|
| VTE-1 | VTE-2 | STK-2 | STK-3 |
| STK-5 | STK-6 | PC-01 (TJC only) | PC-02 (TJC only) |
| PC-05 | PC-06 (TJC only) | ED-2 | OPI-1 |

ORYX: 2021 eCQMs

For any or all of the required chart-abstracted Perinatal Care Measures (PC-01, PC-02, PC-05 and PC-06), **HCOs may submit a minimum of two quarters of eCQM data (ePC-01, ePC-02, ePC-05 and ePC-06) instead of four quarters of the corresponding chart-abstracted measures**

- If an HCO decides to submit all 4 perinatal care eCQMs (ePC-01, ePC-02, ePC-05 and ePC-06) and the HCO has >300 live births, the Joint Commission will consider both the chart-abstracted and eCQM ORYX requirements as complete.

CMS v TJC

| | CMS | | TJC | |
|----------------|---------------|------------------------------|--------|--------------------------------|
| | Status | Required for IQR submission? | Status | Required for ORYX® submission? |
| VTE-1 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| VTE-2 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| ED-2 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| eOPI-1* | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| PC-01 | Retired | No | Active | Yes (Submit any 4 eCQMs) |
| PC-02 | Not available | No | Active | Yes (Submit any 4 eCQMs) |
| PC-05 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| PC-06* | Not available | No | Active | Yes (Submit any 4 eCQMs) |
| STK-2 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| STK-3 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| STK-5 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |
| STK-6 | Active | Yes (Submit any 4 eCQMs) | Active | Yes (Submit any 4 eCQMs) |

Organize, Review & Educate:

Measures, Specifications, Data Elements,
Value Sets / Nomenclature

- 1) ***Bookmark your resources*** - Each eCQM has an associated specification which define the intent, populations, logic, data elements and value sets
- 2) ***Master the measures*** – do your homework, study
- 3) ***Understand your population*** – take expert advice; focus on measures that matter

How does an eCQM work?

- 1) Specification outlines data requirements
- 2) Clinicians document that data in a structured field in the EHR
- 3) Each documentation field is 'mapped' to codes
- 4) Codes drive eCQM results:

No Code / Wrong Code = No Data Evaluation = No Results

ENCOR Electronic Measures

Home Hospital Value Sets Contact Us

Last EH Load: 11/05/2020 06:04 AM
Last CDM Load: 11/05/2020 01:59 AM

eCQM Measure Results

Hospital: January 1, 2020 - December 31, 2020

Regulatory eCQMs Hybrid Measures Medisolv eCQMs

Rate Measure Results

Drag a column header here to group by that column

| | CMS Id | TJC Id | Measure Name | eCQM Version | Initial Population | In Denominator Only | Den. Exclusions | Numerator | Denominator | Exceptions | Rate |
|--|----------|--------|---|--------------|--------------------|---------------------|-----------------|-----------|-------------|------------|---------|
| | | | | | | | | | | | |
| | CMS190v8 | eVTE-2 | Intensive Care Unit Venous Thromboembolism Prophylaxis | 2019 EH | 62 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| | CMS71v9 | eSTK-3 | Anticoagulation Therapy for Atrial Fibrillation/Flutter | 2019 EH | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| | CMS105v8 | eSTK-6 | Discharged on Statin Medication | 2019 EH | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| | CMS72v8 | eSTK-5 | Antithrombotic Therapy By End of Hospital Day 2 | 2019 EH | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| | CMS104v8 | eSTK-2 | Discharged on Antithrombotic Therapy | 2019 EH | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| | CMS506v2 | | Safe Use of Opioids - Concurrent Prescribing | 2019 EH | 12 | 9 | 2 | 1 | 12 | 0 | 10.00 % |
| | CMS108v8 | eVTE-1 | Venous Thromboembolism Prophylaxis | 2019 EH | 62 | 16 | 13 | 33 | 62 | 0 | 67.35 % |

Initial Population

Denominator

Exclusions

Numerator

Exceptions

**Performance Rate = Numerator / Denominator
(minus Exclusions & Exceptions) * 100**

STK-2 Discharged on Antithrombotic Therapy

| | | | |
|---|---|----------------------------|--------------------------------------|
| eCQM Title | Discharged on Antithrombotic Therapy | | |
| eCQM Identifier (Measure Authoring Tool) | 104 | eCQM Version number | 8.1.000 |
| NQF Number | Not Applicable | GUID | 42bf391f-38a3-4c0f-9ece-dcd47e9609d9 |
| Measurement Period | January 1, 20XX through December 31, 20XX | | |
| Measure Steward | The Joint Commission | | |
| Measure Developer | The Joint Commission | | |
| Endorsed By | None | | |
| Description | Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge | | |
| Copyright | LOINC(R) copyright 2004-2018 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2018 International Health Terminology Standards Development Organisation. All Rights Reserved. Measure specifications are in the Public Domain | | |
| Disclaimer | These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The measures and specifications are provided without warranty. | | |
| Measure Scoring | Proportion | | |
| Measure Type | Process | | |
| Stratification | None | | |
| Risk Adjustment | None | | |
| Rate Aggregation | None | | |
| Rationale | <p>The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist.</p> <p>For patients with a stroke due to a cardioembolic source (e.g. atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention, and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke. Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.</p> | | |
| Clinical Recommendation Statement | Clinical trial results suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist | | |
| Improvement Notation | Improvement noted as an increase in rate | | |

STK-2 Discharged on Antithrombotic Therapy

| | |
|-----------------------------------|---|
| Initial Population | Inpatient hospitalizations for patients age 18 and older, discharged from inpatient care (non-elective admissions) with a principal diagnosis of ischemic or hemorrhagic stroke and a length of stay less than or equal to 120 days that ends during the measurement period |
| Denominator | Inpatient hospitalizations for patients with a principal diagnosis of Ischemic stroke |
| Denominator Exclusions | Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations. Inpatient hospitalizations for patients discharged to another hospital Inpatient hospitalizations for patients who left against medical advice Inpatient hospitalizations for patients who expired Inpatient hospitalizations for patients discharged to home for hospice care Inpatient hospitalizations for patients discharged to a health care facility for hospice care Inpatient hospitalizations for patients with comfort measures documented |
| Numerator | Inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge |
| Numerator Exclusions | Not Applicable |
| Denominator Exceptions | Inpatient hospitalizations for patients with a documented reason for not prescribing antithrombotic therapy at discharge. Inpatient hospitalizations for patients who receive Ticagrelor as an antithrombotic therapy during the hospitalization. |
| Supplemental Data Elements | For every patient evaluated by this measure also identify payer, race, ethnicity and sex |

Population logic

STK-2 Discharged on Antithrombotic Therapy

Population Criteria

▲ Initial Population

TJC."Encounter with Principal Diagnosis and Age"

▲ Denominator

TJC."Ischemic Stroke Encounter"

▲ Denominator Exclusions

TJC."Ischemic Stroke Encounters with Discharge Disposition"
union TJC."Comfort Measures during Hospitalization"

▲ Numerator

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
with "Antithrombotic Therapy at Discharge" DischargeAntithrombotic
such that DischargeAntithrombotic.authorDatetime during IschemicStrokeEncounter.relevantPeriod

▲ Numerator Exclusions

None

▲ Denominator Exceptions

"Encounter With No Antithrombotic At Discharge"
union "Encounter With Ticagrelor During Hospitalization"

▲ Stratification

None

Definitions

STK-2 Discharged on Antithrombotic Therapy

Definitions

Antithrombotic Not Given at Discharge

["Medication, Not Discharged": "Antithrombotic Therapy"] NoAntithromboticDischarge
where NoAntithromboticDischarge.negativeRationale in "Medical Reason"
or NoAntithromboticDischarge.negativeRationale in "Patient Refusal"

Antithrombotic Therapy at Discharge

["Medication, Discharge": "Antithrombotic Therapy"]

Denominator

TJC."Ischemic Stroke Encounter"

Denominator Exceptions

"Encounter With No Antithrombotic At Discharge"
union "Encounter With Ticagrelor During Hospitalization"

Denominator Exclusions

TJC."Ischemic Stroke Encounters with Discharge Disposition"
union TJC."Comfort Measures during Hospitalization"

Encounter With No Antithrombotic At Discharge

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
with "Antithrombotic Not Given at Discharge" NoDischargeAntithrombotic
such that NoDischargeAntithrombotic.authorDatetime during IschemicStrokeEncounter.relevantPeriod

Encounter With Ticagrelor During Hospitalization

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
with ["Medication, Administered": TJC."Ticagrelor Therapy"] Ticagrelor
such that Ticagrelor.relevantPeriod starts during Global."HospitalizationWithObservation"(IschemicStrokeEncounter)

Initial Population

TJC."Encounter with Principal Diagnosis and Age"

Numerator

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
with "Antithrombotic Therapy at Discharge" DischargeAntithrombotic
such that DischargeAntithrombotic.authorDatetime during IschemicStrokeEncounter.relevantPeriod

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer"]

SDE Race

["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

TJC.All Stroke Encounter

"Non Elective Inpatient Encounter" NonElectiveEncounter
where NonElectiveEncounter.principalDiagnosis in "Hemorrhagic Stroke"
or NonElectiveEncounter.principalDiagnosis in "Ischemic Stroke"

TJC.Comfort Measures during Hospitalization

"Ischemic Stroke Encounter" IschemicStrokeEncounter
with "Intervention Comfort Measures" ComfortMeasure
such that Coalesce(start of ComfortMeasure.relevantPeriod, ComfortMeasure.authorDatetime) during Global."HospitalizationWithObservation"
(IschemicStrokeEncounter)

STK-2 Discharged on Antithrombotic Therapy

Data Elements are identified in the measure logic and have an associated “Value Set”:

A list of acceptable codes for each data element. The value sets are identified with an OID which is searchable on VSAC (Value Set Authority Center) <https://vsac.nlm.nih.gov>

- code "Birth date" ("LOINC Code (21112-8)")
- valueset "Antithrombotic Therapy" (2.16.840.1.113883.3.117.1.7.1.201)
- valueset "Comfort Measures" (1.3.6.1.4.1.33895.1.3.0.45)
- valueset "Discharge To Acute Care Facility" (2.16.840.1.113883.3.117.1.7.1.87)
- valueset "Discharged to Health Care Facility for Hospice Care" (2.16.840.1.113883.3.117.1.7.1.207)
- valueset "Discharged to Home for Hospice Care" (2.16.840.1.113883.3.117.1.7.1.209)
- valueset "Emergency Department Visit" (2.16.840.1.113883.3.117.1.7.1.292)
- valueset "Ethnicity" (2.16.840.1.114222.4.11.837)
- valueset "Hemorrhagic Stroke" (2.16.840.1.113883.3.117.1.7.1.212)
- valueset "Ischemic Stroke" (2.16.840.1.113883.3.117.1.7.1.247)
- valueset "Left Against Medical Advice" (2.16.840.1.113883.3.117.1.7.1.308)
- valueset "Medical Reason" (2.16.840.1.113883.3.117.1.7.1.473)
- valueset "Non-Elective Inpatient Encounter" (2.16.840.1.113883.3.117.1.7.1.424)
- valueset "Observation Services" (2.16.840.1.113762.1.4.1111.143)
- valueset "ONC Administrative Sex" (2.16.840.1.113762.1.4.1)
- valueset "Patient Expired" (2.16.840.1.113883.3.117.1.7.1.309)
- valueset "Patient Refusal" (2.16.840.1.113883.3.117.1.7.1.93)
- valueset "Payer" (2.16.840.1.114222.4.11.3591)
- valueset "Race" (2.16.840.1.114222.4.11.836)
- valueset "Ticagrelor Therapy" (2.16.840.1.113762.1.4.1110.39)

STK-2 Discharged on Antithrombotic Therapy

Each Value Set contains acceptable codes (nomenclature) and the associated description.

Welcome Search Value Sets Download Browse Code Systems Help

Search the NLM Value Set Repository. Program: CMS eCQM and Hybrid Measure Release: eCQM Update 2019-05-10

Refine by: Steward Code System EP EH CMS eCQM ID (NQF Number) Quality Data Model Category

Query: 2.16.840.1.113762.1.4.1110.39 Search Clear

Search Results API Resource

Results for CMS eCQM and Hybrid Measure : eCQM Update 2019-05-10 : "2.16.840.1.113762.1.4.1110.39"

Select a hyperlinked OID to see its value set details.

Matched Value Sets

| Name | Code System | Definition Type | Steward | OID | Code Count |
|---|-------------|-----------------|----------------------|-------------------------------|------------|
| <input type="checkbox"/> Ticagrelor Therapy | RXNORM | Extensional | The Joint Commission | 2.16.840.1.113762.1.4.1110.39 | 2 |

Value Set Members

Expanded Code List

View Toggle Clear Page 1 of 1 20 View 1 - 2 of 2

| Code | Descriptor | Code System | Version | Code System OID |
|---------|------------------------------|-------------|---------|------------------------|
| 1116635 | Ticagrelor 90 MG Oral Tablet | RXNORM | 2019-01 | 2.16.840.1.113883.6.88 |
| 1666332 | Ticagrelor 60 MG Oral Tablet | RXNORM | 2019-01 | 2.16.840.1.113883.6.88 |

View Page 1 of 1 20 View 1 - 2 of 2

STK-2 Discharged on Antithrombotic Therapy

Value Set Information Expansion Versions: [eCQM Update 2019-05-10](#) [Export Value Set Results](#)

Metadata

Description

Measure

Name: Medical Reason OID: 2.16.840.1.113883.3.117.1.7.1.473

Code System: SNOMEDCT Steward: [Contact](#)
The Joint Commission

Value Set Definition

Definition Type: Extensional Definition Version: [20170726](#)

Program:
CMS, eCQM Update 2019-05-10 using this value set

Expansion Details

Expansion Profile
eCQM Update 2019-05-10 [View](#)

Value Set Members

Expanded Code List

View Toggle Clear Page 1 of 1 20 Row 1 - 18 of 18

| Code | Descriptor | Code System | Version | Code System OID |
|---------------------------|--|-------------|---------|------------------------|
| 183932001 | Procedure contraindicated (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 183964008 | Treatment not indicated (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 183966005 | Drug treatment not indicated (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 266721009 | Absent response to treatment (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 31438003 | Drug resistance (disorder) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 35688006 | Complication of medical care (disorder) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 397745006 | Medical contraindication (finding) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 407563006 | Treatment not tolerated (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 410529002 | Not needed (qualifier value) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 410534003 | Not indicated (qualifier value) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 410536001 | Contraindicated (qualifier value) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 416098002 | Drug allergy (disorder) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 419511003 | Propensity to adverse reactions to drug (disorder) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 428024001 | Clinical trial participant (person) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 428119001 | Procedure not indicated (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 59037007 | Drug intolerance (disorder) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 62014003 | Adverse reaction caused by drug (disorder) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 79899007 | Drug interaction (finding) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |

View Page 1 of 1 20 Row 1 - 18 of 18

Gap Analysis & Roadblocks

CMS 104 Discharged on Antithrombotic Therapy

- **Denominator**

- Non-Elective Inpatients with Ischemic Stroke (principal dx)
- > 18 years of age
- Length of stay < 120 days
- Discharged during reporting period

- **Denominator Exclusions**

- Comfort measures only during hospitalization
- Discharge Dispositions


- **Numerator**

- Antithrombotic Prescribed at Discharge

- **Denominator Exceptions**

- Negation: Medical Reason/Patient Refusal
- Ticagrelor administration during hospitalization

CMS 104 Discharged on Antithrombotic Therapy



eCQMs Roadblocks

- Structured Data
- Nomenclature & Mapping (SNOMED, RxNorm, LOINC, ICD)
- Interpreting results
- Timing
- New data elements
- Logic – complex, doesn't align with workflow, flaws
- Annual updates

Implementation:

Plan, Build, Map, Educate

Implementation

1. Do you have electronic documentation in place currently that can be used to capture eCQM data?
2. Do you have to build new electronic documentation?
3. Have you considered all areas where documentation is captured?
4. Do you have to train new users?
5. Do you have to implement new workflow?

Implementation

▲ Antithrombotic Not Given at Discharge

["Medication, Not Discharged": "Antithrombotic Therapy"] NoAntithromboticDischarge
where NoAntithromboticDischarge.negationRationale in "Medical Reason"
or NoAntithromboticDischarge.negationRationale in "Patient Refusal"

Changes to

Workflow / Documentation

Mapping

Application

Determine

- Who impacted by change?
- Where
- How
- When

Educate

Structured Documentation!

- Discharge Medications
- CPOE
- Nursing Documentation
- Physician Documentation
- Problem List
- eMAR
- OR / ED / OB

Mapping

- 1) Identify current documentation or new documentation to align with data element
- 2) Review and identify code descriptions from value set that align with documentation
- 3) Map codes to appropriate fields in the EHR

Value Set Information Expansion Versions: [eCQM Update 2019-05-10](#) [Export Value Set Results](#)

Metadata
Description
Measure

Name: Medical Reason
Code System: SNOMEDCT
Value Set Definition
Definition Type: Extensional
Definition Version: 20170726
Program: CMS, eCQM Update 2019-05-10 using this value set
Expansion Details
Expansion Profile
eCQM Update 2019-05-10 [View](#)

Value Set Members
Expanded Code List

[View](#) [Toggle](#) [Clear](#) Page 1 of 1 20 rows 1 - 18 of 18

| Code | Descriptor | Code System | Version | Code System OID |
|-----------|--|-------------|---------|------------------------|
| 183932001 | Procedure contraindicated (situation) | SNOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 183964008 | Treatment not indicated (situation) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 183966005 | Drug treatment not indicated (situation) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 266721009 | Absent response to treatment (situation) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 31438003 | Drug resistance (disorder) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 35688006 | Complication of medical care (disorder) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 397745006 | Medical contraindication (finding) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 407563006 | Treatment not tolerated (situation) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 410529002 | Not needed (qualifier value) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 410534003 | Not indicated (qualifier value) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 410536001 | Contraindicated (qualifier value) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 416098002 | Drug allergy (disorder) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 419511003 | Propensity to adverse reactions to drug (disorder) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 428024001 | Clinical trial participant (person) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 428119001 | Procedure not indicated (situation) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 59037007 | Drug intolerance (disorder) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 62014003 | Adverse reaction caused by drug (disorder) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |
| 79899007 | Drug interaction (finding) | NOMEDCT | 2018-09 | 2.16.840.1.113883.6.96 |

[View](#) Page 1 of 1 20 rows 1 - 18 of 18

Validate

Validate

eCQM Measure Results

Hospital: Demo Hospital January 1, 2020 – December 31, 2020

Regulatory eCQMs Hybrid Measures Medisolv eCQMs

Rate Measure Results

Drag a column header here to group by that column

| | CMS Id | TJC Id | Measure Name | eCQM Version | Initial Population | In Denominator Only | Den. Exclusions | Numerator | Denominator | Exceptions | Rate |
|--|----------|--------|---|--------------|--------------------|---------------------|-----------------|-----------|-------------|------------|----------|
| | CMS104v8 | eSTK-2 | Discharged on Antithrombotic Therapy | 2019 EH | 3 | 0 | 1 | 2 | 3 | 0 | 100.00 % |
| | ePC01v8 | ePC-01 | Elective Delivery | 2019 EH | 123 | 1 | 18 | 8 | 27 | 0 | 88.89 % |
| | CMS190v8 | eVTE-2 | Intensive Care Unit Venous Thromboembolism Prophylaxis | 2019 EH | 220 | 1 | 2 | 7 | 10 | 0 | 87.50 % |
| | CMS108v8 | eVTE-1 | Venous Thromboembolism Prophylaxis | 2019 EH | 220 | 67 | 63 | 90 | 220 | 0 | 57.32 % |
| | ePC02v1 | ePC-02 | Cesarean Birth | 2019 EH | 123 | 23 | 0 | 23 | 46 | 0 | 50.00 % |
| | CMS9v8 | ePC-05 | Exclusive Breast Milk Feeding | 2019 EH | 3 | 2 | 0 | 1 | 3 | 0 | 33.33 % |
| | CMS506v2 | | Safe Use of Opioids – Concurrent Prescribing | 2019 EH | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| | CMS71v9 | eSTK-3 | Anticoagulation Therapy for Atrial Fibrillation/Flutter | 2019 EH | 3 | 0 | 1 | 0 | 1 | 0 | 0.00 % |
| | CMS105v8 | eSTK-6 | Discharged on Statin Medication | 2019 EH | 3 | 2 | 1 | 0 | 3 | 0 | 0.00 % |
| | CMS72v8 | eSTK-5 | Antithrombotic Therapy By End of Hospital Day 2 | 2019 EH | 3 | 3 | 0 | 0 | 3 | 0 | 0.00 % |

CMS104v8– Discharged on Antithrombotic Therapy Result: In Numerator Case Identifier: AC0002088865

Conditions Encounters Medications Procedures Lab Tests Allergy/ADR Medical Devices Clinical Documentation QRDA Export (Full Record) » BSON Export (Deidentified Full Record) »



Procedures

Drag a column header here to group by that column


| Case Identifier | Codes | Description | Result | Result Code | Reason | Start Time | End Time | Status | Negation Code | Documentation | Used |
|-----------------|---------------|---|-----------------------|-----------------|--------|-----------------------|-----------------------|-----------|---------------|--|------|
| AC0002088865 | Loinc:72136-5 | Risk for venous thromboembolism | Low (qualifier value) | Snomed:62482003 | | 4/19/2020 11:00:00 AM | 4/19/2020 11:00:00 AM | performed | | RegAcctQuery_Result : PEL.VTE.RFCOMP, Yes Result : RegAcctQuery_Result : PEL.VTE.RFCOMP, Yes | |
| AC0002088865 | Loinc:59408-5 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 95 % | | 4/20/2020 12:18:00 AM | 4/20/2020 12:18:00 AM | performed | | RegAcctQuery_Result : RESP.POSAT, 95 | |

Validate


CMS 105

| Medications  | | | | | | | | |
|---|--------------------------------------|----------------------|----------------------|-----------------------|----------------------|----------------------|--------------------------------|---|
| <i>Click on the header here to group by that column</i> | | | | | | | | |
| Codes | Description | Status | Route | Start Time | End Time | Negation Code | Documentation | Used |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| RxNorm:904475 | Pravastatin Sodium 40 MG Oral Tablet | discharge | | 10/23/2019 5:40:00 PM | | | PRAVASTATIN SOD40 MG, AC, CONT |  |

CMS 108


















| Codes | Description | Status | Route | Start Time | End Time | Negation Code | Documentation | Used |
|----------------------|--|----------------------|--------------------------------------|-----------------------|-----------------------|----------------------|--------------------------------|---|
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| RxNorm:854235 | 0.4 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe | administered | Subcutaneous route (qualifier value) | 12/30/2018 4:51:00 AM | 12/30/2018 4:52:00 AM | | PhaRx, PhaRxMedications: LOV51 |  |

CMS 71

| Codes | Description | Status | Start Time | End Time | Negation Code | Documentation | Used |
|--|-----------------------|----------------------|-----------------------|-----------------------|----------------------|---|---|
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| Oid :2.16.840.1.113883.3.117.1.7.1.200 | Anticoagulant Therapy | discharge not done | 9/16/2019 11:56:00 AM | 9/16/2019 11:56:00 AM | 406149000 | AdmVisitClinicalQueriesMult : CQM.COARE1, 1 |  |

Monitor & Improve

Monitor & Improve


| Rate Measure Results  | | | | | | | | | | | |
|--|---|----------------------|----------------------|---|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Drag a column header here to group by that column | | | | | | | | | | | |
| | | CMS Id | TJC Id | Measure Name | Initial Population | In Denominator Only | Den. Exclusions | Numerator | Denominator | Exceptions | Rate ▾ |
| | | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
|  |  | CMS105v7 | eSTK-6 | Discharged on Statin Medication | 70 | 1 | 14 | 54 | 69 | 0 | 98.18 % |
|  |  | CMS108v7 | eVTE-1 | Venous Thromboembolism Prophylaxis | 3217 | 57 | 1249 | 1911 | 3217 | 0 | 97.10 % |
|  |  | CMS190v7 | eVTE-2 | Intensive Care Unit Venous Thromboembolism Prophylaxis | 3217 | 21 | 140 | 591 | 761 | 9 | 96.57 % |
|  |  | CMS72v7 | eSTK-5 | Antithrombotic Therapy By End of Hospital Day 2 | 70 | 3 | 21 | 45 | 69 | 0 | 93.75 % |
|  |  | CMS104v7 | eSTK-2 | Discharged on Antithrombotic Therapy | 70 | 13 | 14 | 42 | 69 | 0 | 76.36 % |
|  |  | CMS71v8 | eSTK-3 | Anticoagulation Therapy for Atrial Fibrillation/Flutter | 70 | 8 | 7 | 6 | 22 | 1 | 42.86 % |
|  |  | CMS113v7 | ePC-01 | Elective Delivery | 134 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
|  |  | CMS9v7 | ePC-05 | Exclusive Breast Milk Feeding | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |

Monitor & Improve

Who?
How often?

| Rate Measure Results | | | | | | | | | | | |
|---|--|----------|--------|---|--------------------|---------------------|-----------------|-----------|-------------|------------|---------|
| Drag a column header here to group by that column | | | | | | | | | | | |
| | | CMS Id | TJC Id | Measure Name | Initial Population | In Denominator Only | Den. Exclusions | Numerator | Denominator | Exceptions | Rate ▾ |
| | | | | | | | | | | | |
| RE | | CMS105v7 | eSTK-6 | Discharged on Statin Medication | 70 | 1 | 14 | 54 | 69 | 0 | 98.18 % |
| RE | | CMS108v7 | eVTE-1 | Venous Thromboembolism Prophylaxis | 3217 | 57 | 1249 | 1911 | 3217 | 0 | 97.10 % |
| RE | | CMS190v7 | eVTE-2 | Intensive Care Unit Venous Thromboembolism Prophylaxis | 3217 | 21 | 140 | 591 | 761 | 9 | 96.57 % |
| RE | | CMS72v7 | eSTK-5 | Antithrombotic Therapy By End of Hospital Day 2 | 70 | 3 | 21 | 45 | 69 | 0 | 93.75 % |
| RE | | CMS104v7 | eSTK-2 | Discharged on Antithrombotic Therapy | 70 | 13 | 14 | 42 | 69 | 0 | 76.36 % |
| RE | | CMS71v8 | eSTK-3 | Anticoagulation Therapy for Atrial Fibrillation/Flutter | 70 | 8 | 7 | 6 | 22 | 1 | 42.86 % |
| RE | | CMS113v7 | ePC-01 | Elective Delivery | 134 | 0 | 0 | 0 | 0 | 0 | 0.00 % |
| RE | | CMS9v7 | ePC-05 | Exclusive Breast Milk Feeding | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 % |

Monitor & Improve


 CMS108v8– Venous Thromboembolism Prophylaxis Result: In Denominator Only

Conditions Encounters Medications Procedures Lab Tests Allergy/ADR Medical Devices Clinical Documentation

Medical Devices

Drag a column header here to group by that column

| Codes | Description | Start Time | End Time | Status |
|------------------------|---|----------------------|----------------------|----------------------|
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| Snomed:428421000124107 | Intermittent pneumatic compression sleeve (physical object) | 1/8/2020 7:30:00 AM | 1/8/2020 7:30:00 AM | applied |
| Snomed:428421000124107 | Intermittent pneumatic compression sleeve (physical object) | 1/8/2020 7:30:00 AM | 1/8/2020 7:30:00 AM | ordered |

 CMS108v8– Venous Thromboembolism Prophylaxis Result: In Denominator Only

Conditions Encounters Medications Procedures Lab Tests Allergy/ADR Medical Devices Clinical Documentation

Encounters

Drag a column header here to group by that column

| Codes | Decision To Admit Code | Description | Start Time | End Time | Facility Departure | Dis |
|----------------------|------------------------|--|----------------------|----------------------|----------------------|----------------------|
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| Snomed:183452005 | | Emergency hospital admission (procedure) | 1/3/2020 5:00:00 PM | 1/8/2020 11:35:00 AM | | |
| Snomed:4525004 | | Emergency department patient visit (procedure) | 1/3/2020 1:20:00 PM | 1/3/2020 5:00:00 PM | 1/3/2020 5:00:00 PM | |
| Snomed:73607007 | 73607007 | Hospital admission, emergency, from emergency room (procedure) | 1/3/2020 3:16:00 PM | 1/3/2020 3:16:00 PM | | |

Monitor & Improve

1. Regular Team Meetings – group emails & chats
2. Include stakeholders in decision making. Ask for input & feedback!
3. Educate on changes to requirements, measures, workflow
4. Weekly status updates
5. Provide access to eCQM reports and/or dashboards

Gaps and Roadblocks

Gaps and Roadblocks

**Regulatory
Changes**

**EHR Updates,
Migrations**

**Clinical and
Documentation
Changes**

**Mapping
Maintenance**

**Continued
Education**

**Improvement
Hurdles**

Submit

Submission

- ONC Certified (2015)
- Use Correct Version
 - eCQM Specs
 - Value Sets
- QRDA I File Submission
- Vendor Authorization & DDSP Invite
- EHR Certification ID
- HARP (QNET) & DDSP (TJC)
- **Post-Submission Validation**
- Documentation of completion

IQR - HARP

CMS.gov | QualityNet

MEDISOLV INC

Welcome to Hospital Quality Reporting

The cards below display the features available to you. Please select the card that aligns with your task.



My Tasks Page

Return to the new HQR My Tasks page.

Facilities List

All the facilities you have access to upload and manage data for



eCQM

Track status and validation of EHR patient files.



File Upload

Upload files for program credit.



Data Entry

Enter data for program credit.



Files

Accuracy

Outcomes

Upload History

Submission

Test



Change Selection

The table below displays all file uploads. You can view files in either test or production. From here, you can search for other files, or sort the results to view file status and download results.

Search

Search



Reset

Batch File Name

Batch ID

File Size

Upload Date ▼

Uploaded
By

Status

Errors

IQR - Submit

Report Run Date: 11/09/2019

EHR Hospital Reporting – eCQM Performance Summary Report

Submitter: V100359

Discharge Quarter: 01/01/2019 - 03/31/2019

Measure Set: AMI, CAC, ED, HearScreening, Hybrid Measures, PC, PN, SCIP, STK, VTE

Submitter ID: V100359-Medisolv, Inc

Provider ID:

| Measure ID | Version # | IPP | Denominator Population | Numerator Population | Denominator Exclusion | Denominator Exception | Continuous Variable | Performance Score |
|-----------------------------------|-----------|------|------------------------|----------------------|-----------------------|-----------------------|---------------------|-------------------|
| Measure Set: AMI | | | | | | | | |
| AMI-8a | 7 | 21 | 16 | 14 | 0 | 1 | - | 93.3333333 % |
| Measure Set: CAC | | | | | | | | |
| CAC-3 | 6 | 1 | 1 | 1 | - | - | - | 100 % |
| Measure Set: ED | | | | | | | | |
| ED-1 (Stratum 1) | 7 | 2059 | 2059 | 0 | - | - | 335 minutes | - |
| ED-1 (Stratum 2) | 7 | 30 | 30 | 0 | - | - | 366 minutes | - |
| ED-2 (Stratum 1) | 7 | 1954 | 1954 | 0 | - | - | 298 minutes | - |
| ED-2 (Stratum 2) | 7 | 30 | 30 | 0 | - | - | 313.5 minutes | - |
| Measure Set: HearScreening | | | | | | | | |
| EHDI-1a | 7 | 231 | 231 | 231 | 0 | - | - | 100 % |
| Measure Set: PC | | | | | | | | |
| PC-01* | 7 | 181 | 26 | 6 | 0 | - | - | 23.0769231 % |
| PC-05 | 7 | 201 | 201 | 55 | 30 | - | - | 32.1637427 % |
| Measure Set: STK | | | | | | | | |
| STK-2 | 7 | 39 | 30 | 24 | 6 | 0 | - | 100 % |
| STK-3 | 8 | 39 | 8 | 4 | 3 | 0 | - | 80 % |
| STK-5 | 7 | 39 | 30 | 22 | 5 | 1 | - | 91.6666667 % |
| STK-6 | 7 | 39 | 30 | 19 | 6 | 3 | - | 90.4761905 % |
| Measure Set: VTE | | | | | | | | |
| VTE-1 | 7 | 2261 | 2261 | 1716 | 538 | - | - | 99.5937319 % |
| VTE-2 | 7 | 2261 | 236 | 196 | 39 | 1 | - | 100 % |

Rate Measure Results

Drag a column header here to group by that column

| | CMS Id | TJC Id | Measure Name | eCQM Version | Initial Population | In Denominator Only | Den. Exclusions | Numerator | Denominator | Exceptions | Rate |
|--|----------|--------|-------------------|--------------|--------------------|---------------------|-----------------|-----------|-------------|------------|---------|
| | | | | | | | | | | | |
| | CMS113v7 | ePC-01 | Elective Delivery | 2018 EH | 181 | 9 | 16 | 1 | 26 | 0 | 10.00 % |

TJC - DDSP

Submitting for:

Switch

eCQM Status: **Submitted**

Chart-Abstracted Status: **Q1 2020 Complete**

Download Report

eCQM submission period for 2020 is Open

Submission period closes on 03-15-2021 at 8pm CST

eCQM Annual Submission Status (140 Hospitals)

0 eCQM Module Disabled

0 eCQM ECR on File

82 Unsubmitted

0 Withdrawn

58 Submitted



CY 2020 Direct Data Submission Platform

page: 1 of 1

eCQM Submission Report

Submitted on: Aug 17, 2020 6:12 PM UTC By:

| Measure | Initial Population | Denominator | Numerator | Rate / Observation | Zero Den. Cases? | Threshold Exemption? | Zero IP Cases? |
|----------------|--------------------|-------------|-----------|--------------------|------------------|----------------------|----------------|
| Quarter 1 2020 | | | | | | | |
| eED2a | 37 | 37 | - | 40.0 | | | |
| eED2b | 37 | 35 | - | 43.0 | | | |
| eED2c | 37 | 2 | - | 3.0 | | | |
| eSTK2 | 1 | 0 | 0 | - | ✓ | | |
| eSTK5 | 1 | 1 | 1 | 100.00% | | | |
| eVTE1 | 119 | 79 | 66 | 83.54% | | | |

TJC - DDSP

Data Accuracy Quality Improvement

Quality Improvement

Measure
eED2a

Active Patients
37

Total Episodes of Care
40

Select Measures


eED2a

Select Quarter

quarter

2020Q1

Population Breakdown for the Selected Measure (Episodes of Care)



Clear Selection

Active Documents (37)

QRDA Documents without Errors

Search documents

Search

| | |
|------|---------|
| 54ac | 12.xml |
| 54ac | 37.xml |
| 54ac | 5d.xml |
| 54ac | 52.xml |
| 54ac | 1e.xml |
| 54ac | 14.xml |
| 54ac | 13.xml |
| 54ac | 1b.xml |
| 54ac | 13.xml |
| 54ac | 1e.xml |
| 54ac | 11.xml |
| 54ac | 1.xml |
| 54c9 | 1df.xml |
| 5550 | 6f.xml |
| 557a | 6d.xml |
| 557a | 6.xml |


Results by Measure

Rules engine results for measures by quarter.

| | 2020Q1 | |
|-------|--------------------|---------------------------|
| | Initial Population | Observed Rate/Observation |
| eED2a | 37 | 40 |
| eED2b | 37 | 43 |
| eED2c | 37 | 3 |
| eSTK2 | 1 | - |
| eSTK5 | 1 | 100% |
| eVTE1 | 119 | 83.54% |

Review patient results


Year 2: Maintaining the Foundation



Verify Team & Update Resources



Review Regulatory Requirement Changes



Review Changes: Measures, Specifications...



Update Gap Analysis / Roadblocks



Review Data Capture, Mapping – Implement Updates



Validate



Monitor & Improve



Submit

Maintaining the Foundation

2020 Reporting:

Denominator Exceptions

"Encounter With No Antithrombotic At Discharge"
union "Encounter With Ticagrelor During Hospitalization"

| Value Set Members | | | | |
|--|------------------------------|-------------|---------|------------------------|
| Expanded Code List | | | | |
| View Toggle Clear Page 1 of 1 20 View 1 - 2 of 2 | | | | |
| Code | Descriptor | Code System | Version | Code System OID |
| 1116635 | Ticagrelor 90 MG Oral Tablet | RXNORM | 2019-01 | 2.16.840.1.113883.6.88 |
| 1666332 | Ticagrelor 60 MG Oral Tablet | RXNORM | 2019-01 | 2.16.840.1.113883.6.88 |

2021 Reporting:

Denominator Exceptions

"Encounter With No Antithrombotic At Discharge"
union "Encounter With Pharmacological Contraindications for Antithrombotic Therapy at Discharge"

| Value Set Members | | | | |
|--|------------------------------|-------------|---------|------------------------|
| Expanded Code List | | | | |
| View Toggle Clear Page 1 of 1 20 View 1 - 4 of 4 | | | | |
| Code | Descriptor | Code System | Version | Code System OID |
| 1116635 | Ticagrelor 90 MG Oral Tablet | RXNORM | 2020-01 | 2.16.840.1.113883.6.88 |
| 1666332 | Ticagrelor 60 MG Oral Tablet | RXNORM | 2020-01 | 2.16.840.1.113883.6.88 |
| 855812 | prasugrel 10 MG Oral Tablet | RXNORM | 2020-01 | 2.16.840.1.113883.6.88 |
| 855818 | prasugrel 5 MG Oral Tablet | RXNORM | 2020-01 | 2.16.840.1.113883.6.88 |

Share & Celebrate Success!

ENCOR Electronic Measures

Home Hospital Value Sets Contact Us

Last EH Load: 10/14/2020 08:20 AM

eCQM Measure Results

Hospital:

July 1, 2020 – September 30, 2020

Regulatory eCQMs Hybrid Measures Medisolv eCQMs

Rate Measure Results

Drag a column header here to group by that column

| | CMS Id | TJC Id | Measure Name | eCQM Version | Initial Population | In Denominator Only | Den. Exclusions | Numerator | Denominator | Exceptions | Rate |
|--|----------|--------|---|--------------|--------------------|---------------------|-----------------|-----------|-------------|------------|----------|
| | | | | | | | | | | | |
| | CMS72v8 | eSTK-5 | Antithrombotic Therapy By End of Hospital Day 2 | 2019 EH | 49 | 0 | 8 | 40 | 49 | 0 | 100.00 % |
| | CMS71v9 | eSTK-3 | Anticoagulation Therapy for Atrial Fibrillation/Flutter | 2019 EH | 49 | 0 | 2 | 3 | 49 | 0 | 100.00 % |
| | CMS190v8 | eVTE-2 | Intensive Care Unit Venous Thromboembolism Prophylaxis | 2019 EH | 1636 | 6 | 41 | 262 | 313 | 4 | 97.76 % |
| | CMS105v8 | eSTK-6 | Discharged on Statin Medication | 2019 EH | 49 | 1 | 6 | 38 | 48 | 3 | 97.44 % |
| | CMS108v8 | eVTE-1 | Venous Thromboembolism Prophylaxis | 2019 EH | 1636 | 46 | 495 | 1095 | 1636 | 0 | 95.97 % |
| | CMS104v8 | eSTK-2 | Discharged on Antithrombotic Therapy | 2019 EH | 49 | 2 | 6 | 40 | 48 | 0 | 95.24 % |



Kristen Beatson
Director, Electronic Measures
kbeatson@medisolv.com

Questions?